Patrick Caron

Patrick Caron

Auto-generated profile, based on publicly available information

Patrick Caron

Université Laval, Québec City, Québec, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Hepatology
Verified
Journal Article
Closed access
JPJessica L. Petrick
Jessica L. Petrick
AFAndrea A. Florio
Andrea A. Florio
XZXuehong Zhang
Xuehong Zhang
AZAnne Zeleniuch‐Jacquotte
Anne Zeleniuch‐Jacquotte
PWProf. Dr. Jean Wactawski-Wende
Prof. Dr. Jean Wactawski-Wende
KMKatherine McGlynn
Katherine McGlynn

1 April 2016 in European Urology
Verified
Journal Article
Closed access
ABAnaïs Belledant
Anaïs Belledant
HHHélène Hovington
Hélène Hovington
LGLuciana Garcia
Luciana Garcia
PCPatrick Caron
Patrick Caron
HBHervé Brisson
Hervé Brisson
ÉLÉric Lévesque
Éric Lévesque


22 March 2023 in JHEP Reports
Verified
Journal Article
Open access
ZWZeni Wu
Zeni Wu
JPJessica L. Petrick
Jessica L. Petrick
AFAndrea A. Florio
Andrea A. Florio
Chantal GuillemetteChantal Guillemette
Chantal Guillemette
LFLaura E. Beane Freeman
Laura E. Beane Freeman
KMKatherine McGlynn
Katherine McGlynn
Incidence rates of liver cancer in most populations are two to three times higher among men than women. The higher rates among men have led to the suggestion that androgens are related to increased risk whereas oestrogens are related to decreased risk. This hypothesis was investigated in the present study via a nested case-control analysis of pre-diagnostic sex steroid hormone levels among men in five US cohorts. Concentrations of sex steroid hormones and sex hormone-binding globulin were quantitated using gas chromatography–mass spectrometry and a competitive electrochemiluminescence immunoassay, respectively. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% CIs for associations between hormones and liver cancer among 275 men who subsequently developed liver cancer and 768 comparison men. Higher concentrations of total testosterone (OR per one-unit increase in log2 = 1.77, 95% CI = 1.38–2.29), dihydrotestosterone (OR = 1.76, 95% CI = 1.21–2.57), oestrone (OR = 1.74, 95% CI = 1.08-2.79), total oestradiol (OR = 1.58, 95% CI=1.22–20.05), and sex hormone-binding globulin (OR = 1.63, 95% CI = 1.27–2.11) were associated with increased risk. Higher concentrations of dehydroepiandrosterone (DHEA), however, were associated with a 53% decreased risk (OR = 0.47, 95% CI = 0.33–0.68). Higher concentrations of both androgens (testosterone, dihydrotestosterone) and their aromatised oestrogenic metabolites (oestrone, oestradiol) were observed among men who subsequently developed liver cancer compared with men who did not. As DHEA is an adrenal precursor of both androgens and oestrogens, these results may suggest that a lower capacity to convert DHEA to androgens, and their subsequent conversion to oestrogens, confers a lower risk of liver cancer, whereas a greater capacity to convert DHEA confers a greater risk. This study does not fully support the current hormone hypothesis as both androgen and oestrogen levels were associated with increased risk of liver cancer among men. The study also found that higher DHEA levels were associated with lower risk, thus suggesting the hypothesis that greater capacity to convert DHEA could be associated with increased liver cancer risk among men.

1 April 2019 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
ÉLÉric Lévesque
Éric Lévesque
PCPatrick Caron
Patrick Caron
LLLouis Lacombe
Louis Lacombe
VTVéronique Turcotte
Véronique Turcotte
DSDavid Simonyan
David Simonyan
Chantal GuillemetteChantal Guillemette
Chantal Guillemette
Background: In men with localized prostate cancer who are undergoing radical prostatectomy (RP), it is uncertain whether their systemic hormonal environment is associated with outcomes. The objective of the study was to examine the association between the circulating steroid metabolome with prognostic factors and progression. Methods: The prospective PROCURE cohort was recruited from 2007 to 2012, and comprises 1,766 patients with localized prostate cancer who provided blood samples prior to RP. The levels of 15 steroids were measured in plasma using mass spectrometry, and their association with prognostic factors and disease-free survival (DFS) was established with logistic regression and multivariable Cox proportional hazard models. Results: The median follow-up time after surgery was 73.2 months. Overall, 524 patients experienced biochemical failure and 75 developed metastatic disease. Testosterone and androsterone levels were higher in low-risk disease. Associations were observed between adrenal precursors and risk of cancer progression. In high-risk patients, a one-unit increment in log-transformed androstenediol (A5diol) and dehydroepiandrosterone-sulfate (DHEA-S) levels were linked to DFS with HR of 1.47 (P = 0.0017; q = 0.026) and 1.24 (P = 0.043; q = 0.323), respectively. Although the number of metastatic events was limited, trends with metastasis-free survival were observed for A5diol (HR = 1.51; P = 0.057) and DHEA-S levels (HR = 1.43; P = 0.054). Conclusions: In men with localized prostate cancer, our data suggest that the preoperative steroid metabolome is associated with the risk of recurrence of high-risk disease. Impact: The associations of adrenal androgens with progression of localized high-risk disease could help refine hormonal strategies for these patients.

1 November 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PTPaul Toren
Paul Toren
AHAzik Hoffman
Azik Hoffman
KDKeyue Ding
Keyue Ding
FJFrance-Hélène Joncas
France-Hélène Joncas
VTVéronique Turcotte
Véronique Turcotte
LKLaurence H Klotz
Laurence H Klotz
Purpose: Phenotypic biomarkers are a high priority for patients receiving androgen deprivation therapy (ADT) for prostate cancer given the increasing number of treatment options. This study evaluates serum sex steroids as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. Experimental Design: Retrospective cohort study of Canadian patients in the PR.7 trial (accrual 1999-2005) who received continuous ADT for biochemical recurrence post-radiotherapy. Patients were excluded with follow-up <2 years or who received estrogens or corticosteroids. Kaplan-Meier and multivariable cox regression analyses adjusted for baseline prognostic factors assessed time to castration resistance prostate cancer(CRPC), prostate cancer survival and overall survival according to tertile of sex steroid measured by mass spectrometry. Results: Post-ADT initiation, we measured samples in 219 patients as well as 2 subsequent annual samples in a subset of 101 patients. Testosterone levels correlated with androstenedione (AD) and dihydrotestosterone (DHT), while DHT, AD, androsterone (AST), dehydroepiandrosterone (DHEA) and androstenediol (A5diol) were highly correlated to each other and negatively associated with age. Higher tertiles of estrone(E1) and estradiol(E2) were significantly associated with sooner time to CRPC. In patients with longitudinal samples, increases in serum DHEA and AST were significantly associated with sooner time to CRPC. Limitations include the number of events for some groups. Conclusions: Our data suggest the patient hormonal milieu has long-term prognostic value in men receiving ADT for recurrent prostate cancer, including increased levels of E1 and E2 and rising DHEA and AST levels which predict a shorter time to CRPC.